## Mats Eriksson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/708832/publications.pdf

Version: 2024-02-01

758635 642321 1,109 23 12 23 citations h-index g-index papers 23 23 23 1622 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	<i>Soat2</i> ties cholesterol metabolism to βâ€oxidation and glucose tolerance in male mice. Journal of Internal Medicine, 2022, 292, 296-307.	2.7	6
2	Prevalence of Subclinical Coronary Artery Atherosclerosis in the General Population. Circulation, 2021, 144, 916-929.	1.6	164
3	Diiodothyronines regulate metabolic homeostasis in primary human hepatocytes by modulating mTORC1 and mTORC2 activity. Molecular and Cellular Endocrinology, 2020, 499, 110604.	1.6	5
4	Weight gain and blood pressure. Journal of Hypertension, 2020, 38, 387-394.	0.3	7
5	Lomitapide treatment in a female with homozygous familial hypercholesterolaemia: a case report. European Heart Journal - Case Reports, 2020, 4, 1-6.	0.3	2
6	Generation of new hepatocyte-like in vitro models better resembling human lipid metabolism. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158659.	1.2	2
7	How to handle hypertriglyceridaemia in acute pancreatitis – Still a vote for conservatives?. Journal of Internal Medicine, 2019, 286, 723-725.	2.7	3
8	Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population: estimates from Swedish population-based register data. European Heart Journal Quality of Care & Clinical Outcomes, 2019, 5, 225-232.	1.8	30
9	Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients. Journal of the American Heart Association, 2018, 7, e009876.	1.6	24
10	Effect of Statin Treatment on Plasma 4βâ€Hydroxycholesterol Concentrations. Basic and Clinical Pharmacology and Toxicology, 2016, 118, 499-502.	1.2	10
11	LEADER-6: Baseline renal function and associated factors in a high cardiovascular risk type 2 diabetes population. Journal of Diabetes and Its Complications, 2016, 30, 1631-1639.	1.2	5
12	Statin-induced myopathy in a usual care settingâ€"a prospective observational study of gender differences. European Journal of Clinical Pharmacology, 2016, 72, 1171-1176.	0.8	15
13	Culturing of HepG2 cells with human serum improve their functionality and suitability in studies of lipid metabolism. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2016, 1861, 51-59.	1.2	11
14	Children with autism spectrum disorders who do not develop phrase speech in the preschool years. Autism, 2015, 19, 934-943.	2.4	120
15	Reductions in serum levels of <scp>LDL</scp> cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liverâ€selective thyroid hormone receptor agonist eprotirome. Journal of Internal Medicine, 2015, 277, 331-342.	2.7	43
16	Role of TG-interacting factor (Tgif) in lipid metabolism. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2015, 1851, 9-12.	1.2	7
17	Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145). Journal of the American College of Cardiology, 2014, 63, 1278-1288.	1.2	316
18	Cholesteryl esters and ACAT. European Journal of Lipid Science and Technology, 2012, 114, 624-633.	1.0	21

#	Article	IF	CITATIONS
19	Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial. Advances in Therapy, 2011, 28, 811-823.	1.3	31
20	Long-term efficacy of pitavastatin versus simvastatin. Advances in Therapy, 2011, 28, 799-810.	1.3	29
21	Blood lipids in 75,048 type 2 diabetic patients: a population-based survey from the Swedish National diabetes register. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 97-105.	3.1	28
22	Stimulation of Fecal Steroid Excretion After Infusion of Recombinant Proapolipoprotein A-I. Circulation, 1999, 100, 594-598.	1.6	228
23	Cholecystokinin peptides in cerebrospinal fluid: a pilot study in hypothyroid patients. Human Psychopharmacology, 1999, 14, 113-117.	0.7	2